NEW YORK, Aug. 8, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Corindus Vascular Robotics, Inc. ("Corindus" or the "Company") (NYSE: CVRS) in connection with the proposed acquisition of the Company by a subsidiary of Siemens Healthineers AG ("Siemens Healthineers"). Under the terms of the agreement, Corindus shareholders will receive $4.28 per CVRS share.
If you own CVRS shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
[email protected]
Visit our website
http://www.weisslawllp.com/corindus-vascular-robotics-inc/
Or follow us on Twitter @MarketsAlert
WeissLaw is investigating whether Corindus's Board acted to maximize shareholder value prior to entering into the acquisition agreement. According to the acquisition announcement, Siemens Healthineers hopes to use the Company's established position in vascular robotics and strong technology platform in robotic-assisted procedures to drive its own growth in the vascular robotics industry.
Given these facts, WeissLaw is concentrating its investigation on whether the acquisition enhances shareholder value. WeissLaw is also concerned whether the proposed acquisition undervalues the Company, and whether all material information related to the proposed acquisition is fully and fairly disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]
SOURCE WeissLaw LLP
![](https://rt.prnewswire.com/rt.gif?NewsItemId=DC37307&Transmission_Id=201908081656PR_NEWS_USPR_____DC37307&DateId=20190808)
Share this article